Human monoclonal antibodies against AXL

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10398774
APP PUB NO 20170340734A1
SERIAL NO

15534178

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)101 RUE DE TOLBIAC PARIS F-75013
UNIVERSITÉ DE MONTPELLIER34090 MONTPELLIER
INSTITUT REGIONAL DU CANCER DE MONTPELLIER208 RUE DES APOTHICAIRES F-34090 MONTPELLIER F-34090

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Larbouret, Christel Montpellier, FR 11 61
Martineau, Pierre Montpellier, FR 21 52
Poul, Marie-Alix Montpellier, FR 5 24
Robert, Bruno Montpellier, FR 19 258

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 3, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 3, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00